Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • GENERAL HEALTH CARE NEWS—9th Cir.: Breach of confidence constitutes injury-in-fact sufficient to confer Article III standing
    • ADMINISTRATION OF FDC ACT—NOTICES: Determination that oxandrin (oxandrolone) tablets, 2.5mg and 10mg, were withdrawn from sale for reasons of safety or effectiveness
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • ADMINISTRATION OF MEDICARE/MEDICAID PROGRAMS—DAB DECISIONS: Twenty-year exclusion from Medicare, Medicaid affirmed for $3M fraud loss, other aggravating factors
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • ANTITRUST—N.D. Ill.: Health plan’s suit seeking damages against AbbVie over drug pricing dismissed
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • FRAUD AND ABUSE—OIG REPORTS: 90% of Medicaid reimbursements for Wisconsin’s school-based program may have been improperly claimed
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • GENERAL HEALTH CARE NEWS—FINAL RULES: Removal of obsolete, suspended HIS regulations
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • LABELING AND PACKAGING (FOOD, DRUGS & MEDICAL DEVICES)—9th Cir.: Hair care manufacturer secures reversal of class certification in animal-testing labeling suit
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • QUALITY OF CARE—DAB DECISIONS: Quality-of-Care requirements mandate timely assessment, monitoring, physician notification post-changes in resident condition
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • REGULATION TRACKER—Information on pending or recently adopted regulations and regulation amendments
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • WORTH NOTING—Other Health Law litigation and regulatory developments
      • You have 1 more complimentary views available this month. Log in if you are already a customer
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, ADMINISTRATION OF FDC ACT—NOTICES: Determination that oxandrin (oxandrolone) tablets, 2.5mg and 10mg, were withdrawn from sale for reasons of safety or effectiveness, (Oct 13, 2026)

    By WK Editorial Staff

    Corrections made to address ANDA changes.

    The FDA corrected a notice that appeared in the Federal Register of September 13, 2023 (88 Fed. Reg. 62799). The notice announced the determination that oxandrin (oxandrolone) tablets, 2.5 milligrams (mg) and ...

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use